Teva Pharmaceutical (TEVA) Stock Price
$15.42 2.2%
to add to portfolio
AI Score
-
Alternative
4 -
Fundamental
3 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Teva Pharmaceutical, AI stock picks, stock alerts and much more.
TEVA AI Stock Analysis
AI stock analysis for TEVA is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Teva Pharmaceutical (TEVA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Teva Pharmaceutical (TEVA) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Teva Pharmaceutical (TEVA), currently trading at $15.42, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About TEVA
-
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.
-
Symbol
TEVA
-
Market
NYSE
-
Industry
Drug Manufacturers - Specialty & Generic
-
Market Cap
17.7B
Similar Stocks
 |
Zoetis ZTS |
$163.5 0.3% |
5 |
 |
Elanco Animal Health ELAN |
$10.31 1% |
4 |
News
TEVA Alternative Data
Web Traffic
Teva Pharmaceutical receives an estimated 123659 monthly visitors to tevapharm.com.
-
Web Traffic
123659
-
Change from Previous Month
14.1%
-
3 Month Change
18%
-
YoY Change
18%
News Mentions
Teva Pharmaceutical was mentioned 7 times in the news yesterday.
-
News Mentions
7
-
Daily Change
600%
-
1 Month Change
0%
-
3 Month Change
22.2%
Reddit Mentions
Teva Pharmaceutical has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
Twitter Followers
Teva Pharmaceutical has 10,693 Twitter Followers on its main Twitter (also known as X) account, which is down by -0% over the last month.
-
Twitter Followers
10693
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.1%
-
YoY Change
0.1%
Facebook Engagement
Teva Pharmaceutical has engaged 59 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
59
-
Daily Change
3.5%
-
1 Month Change
47.5%
-
3 Month Change
34.1%
-
YoY Change
34.1%
Youtube Subscribers
Teva Pharmaceutical has 8,350 subscribers on its main Youtube channel, up by 0.8% over the last month.
-
Youtube Subscribers
8350
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
1.8%
-
YoY Change
1.8%
Job Postings
Teva Pharmaceutical has an estimated 485 open job postings, which is down -11.8% over the last month.
-
Job Postings
485
-
Daily Change
2.4%
-
1 Month Change
11.8%
-
3 Month Change
32.2%
-
YoY Change
32.2%
LinkedIn Employees
According to LinkedIn, Teva Pharmaceutical has 29,726 employees, up by 0.3% over the last month.
-
LinkedIn Employees
29726
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
4.5%
-
YoY Change
4.5%
Business Outlook
According to employee reviews, the business outlook among employees at Teva Pharmaceutical is 59 out of 100 (neutral).
-
Business Outlook
59
-
Change from Previous Month
1.7%
-
3 Month Change
0%
-
YoY Change
0%
TEVA Financials
TEVA Key Metrics
-
Total Revenue
$4.2B
-
Net Income
-$217M
-
Earnings per Share
-$0.19
-
Free cash flow
$446M
-
EBITDA
-$29M
-
EBITDA Ratio
-0.00685741
-
Total Assets
$39.3B
TEVA 2-year Revenue & Income
TEVA 2-year Free Cash Flow
TEVA Technicals
TEVA SMA
TEVA RSI
FAQ
What's the current price of Teva Pharmaceutical (TEVA) Stock?
The price of an Teva Pharmaceutical (TEVA) share is $15.42.
What's the market cap of Teva Pharmaceutical?
The current market cap of Teva Pharmaceutical is 17.7B.
Should I buy or sell TEVA?
Teva Pharmaceutical exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Teva Pharmaceutical a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Teva Pharmaceutical stock. There are several bearish signals and market challenges that could negatively impact Teva Pharmaceutical's future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Teva Pharmaceutical (TEVA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Teva Pharmaceutical stock right now, as the outlook appears bearish.
What are some stocks similar to Teva Pharmaceutical (TEVA) that investors often compare it to?
Teva Pharmaceutical (TEVA) is often compared to similar stocks such as Zoetis and Elanco Animal Health.
What is the forecast for Teva Pharmaceutical's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Teva Pharmaceutical's stock price to be around $14.33 in 2026. Starting from the current price of $15.42, this represents a 7.1% change in price, indicating a bearish outlook for the stock.
How to buy Teva Pharmaceutical (TEVA) Stock?
Teva Pharmaceutical stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Teva Pharmaceutical shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.